Olink Holding AB (publ) (OLK)

Market Cap	2.79B
Revenue (ttm)	169.60M
Net Income (ttm)	-31.60M
Shares Out	124.34M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	185.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	244,274
Open	22.03
Previous Close	22.20
Day's Range	22.03 - 22.63
52-Week Range	14.10 - 26.01
Beta	0.50
Analysts	Hold
Price Target	26.00 (+15.92%)
Earnings Date	May 9, 2024

About OLK

Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom de...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Mar 25, 2021
• Employees: 707
• Stock Exchange: NASDAQ
• Ticker Symbol: OLK

Financial Performance

In 2023, OLK's revenue was $169.60 million, an increase of 21.27% compared to the previous year's $139.85 million. Losses were -$31.60 million, 145.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for OLK stock is "Hold." The 12-month stock price forecast is $26.0, which is an increase of 15.92% from the latest price.

Price Target

$26.0

(15.92% upside)

Analyst Consensus: Hold